Introduction {#s1}
============

Age-related changes to the innate and adaptive immune system can increase susceptibility to tuberculosis (TB) infection or the reactivation of latent TB infection (LTBI) in older patients \[[@C1]\]. The global increase in ageing means that those aged ≥65 years are expected to account for 16% of the world\'s population by 2050, a proportion expected to rise much faster in developing countries (a 250% increase) compared with developed countries (a 71% increase) \[[@C2]\]. More than 95% of the burden of TB is in low- and middle-income countries (LMICs) \[[@C3], [@C4]\], with the older population increasing as a proportion of patients with TB \[[@C5], [@C6]\]. There is also likely to be a burden of undetected TB among the elderly, particularly in LMICs \[[@C4]\]. For older patients, the higher rate of TB is likely a combination of cumulative years with LTBI, age-related immunosenescence, comorbidities and immunosuppressive therapy \[[@C4]\].

TB in the elderly presents with fewer of the classical symptoms of TB \[[@C1], [@C6]--[@C9]\], less specific radiological changes \[[@C10], [@C11]\] and more comorbidities \[[@C9], [@C12]\] than in younger patients, and it has even been proposed that TB in older adults should be considered as a different disease entity \[[@C13]\]. The classical TB symptoms of cough, haemoptysis, fever, drenching night sweats and weight loss may not be as evident in older patients. Less specific symptoms, such as weakness, dyspnoea, anorexia and mental change, are seen more frequently in older patients with TB compared with younger patients \[[@C1], [@C13], [@C14]\]. In addition, comorbidities that are more common in older patients may mask the symptoms of TB, *e.g.* those with chronic cough due to chronic obstructive pulmonary disease (COPD) may have a delayed presentation or diagnosis. However, conversely, they may have closer healthcare contact.

UK surveillance data show that the proportion of TB patients who experienced a delay of \>4 months from symptom onset to starting treatment increases with age, from 24.9% in those aged 15--44 years to 38.6% among those aged ≥65 year olds \[[@C15]\]. The reasons for this are numerous, and likely relate to a combination of patient-related and health system delays. Patient-related delay refers to the time from symptom onset to first seeking healthcare, whereas provider delay occurs within the healthcare system \[[@C16]\]. The less typical symptomatology and radiology among the elderly contributed to patient and healthcare system-related delays in some \[[@C10], [@C17], [@C18]\] but not all cohorts \[[@C19], [@C20]\]. For patient-related delays, there may be challenges to recall of type and duration of symptoms on presenting either to secondary care; this may be disproportionately affect older compared with younger patients with TB.

There are few recent studies that explore the differences between older and younger TB patients in a UK setting. TB in older adults is increasingly important given ageing in LMICs where the burden of TB is greatest. It is associated with comorbidities and polypharmacy, increased side-effects, and poorer outcomes, thereby placing increased demand per patient on clinical services \[[@C21]\]. In this study, we compare the clinical and radiological presentation of TB in adult patients aged 18--64 or ≥65 years and factors (including age) associated with time to diagnosis and treatment in a London-based cohort. This cohort represents a high TB burden area in an otherwise low TB incidence country, which may be similar to other urban areas in Western Europe.

Methods {#s2}
=======

Study design {#s2a}
------------

We undertook a retrospective study comparing patients aged ≥65 years with patients aged 18--64 years. The aim was to compare the clinical and radiological features at presentation to secondary care, the duration of symptoms at presenting to secondary care, the time from presentation to secondary care to starting treatment and the total time from symptom onset to starting treatment between the two groups.

Factors that may influence time to presentation and treatment were examined: age, ethnicity, place of birth (UK born *versus* non-UK born), sex, comorbidities (diabetes, renal failure, cancer, HIV and respiratory conditions, including COPD, asthma, bronchiectasis and pulmonary fibrosis). In addition, we also analysed differences by site of TB (extrapulmonary TB (EPTB) *versus* pulmonary TB (PTB)) and PTB smear status.

Study site and patient cohort {#s2b}
-----------------------------

A list of all patients treated for TB at Northwick Park Hospital (London, UK) between 2002 and 2015 was downloaded from the London TB Register. All TB patients aged ≥65 years who began treatment from January 1, 2002 to December 31, 2015 were included. We randomly selected a twofold larger sample of patients aged 18--64 years from the register for the period 2011--2015 (because clinical data recording improved from 2011 onwards). Northwick Park Hospital is part of London North West Healthcare NHS Trust, which has one of the largest TB units in the UK (and in Western Europe), treating 600 TB patients per year during 2010--2014.

Data collection {#s2c}
---------------

The following data were extracted from electronic records in secondary care: symptoms (nature of symptoms and symptom duration at presentation to secondary care, including presence of cough, haemoptysis, fever, drenching night sweats, weight loss, dyspnoea, lethargy and reduced appetite), clinical (site or sites of TB) and baseline radiology (chest radiograph most closely preceding start of treatment with features including cavitation, consolidation, nodules, miliary, lymphadenopathy and effusion). For radiology, data were extracted from reports when each of the parameters of interest was reported. Cavitations imply the presence of a cavity; nodules are small masses of tissue visible seen on chest radiography; miliary refers to the presence of uniformly distributed 1--3 mm diameter nodules on chest radiography.

Data were also collected on baseline biochemistry and haematology (full blood count, erythrocyte sedimentation rate, renal function, electrolytes, albumin, alanine aminotransferase, alkaline phosphatase, bilirubin and 25-hydroxy-vitamin D level), and treatment (time to starting treatment and symptom onset to starting treatment). Access to primary care records was not possible except where referral letters were uploaded onto the secondary care system.

Baseline biochemical and haematological data were extracted from medical records for groups of patients aged ≥65 and 25--35 years. Data from patients aged 25--35 years were chosen in order to compare elderly patients with patients in the age range representing the majority of TB patients in our centre.

Time to presentation and start of treatment {#s2d}
-------------------------------------------

To investigate possible age-related delays in treatment and other factors potentially associated with treatment delays, time periods were classified as: 1) pre-secondary care (*i.e.* before first attendance at hospital), encompassing patient-related and primary healthcare factors, hereafter referred to as "time to presentation" (this period is affected by recall bias of what is reported by the patient either in primary care or secondary care and what is recorded in the primary care referral letter to secondary care); 2) post-secondary care (*i.e.* after attendance at hospital), describing the period between being first seen at secondary care to starting treatment for TB, hereafter referred to as "time from presentation" (this includes time for investigations); and 3) total time from symptom onset to commencing TB treatment, hereafter referred to as "time to treatment". These chosen time periods encompass the patient\'s journey from symptom onset to starting treatment and allow for comparison with published literature.

Statistical analysis {#s2e}
--------------------

Baseline (at time of admission) demographic and clinical characteristics of patients aged ≥65 years were compared with characteristics of patients aged 18--64 years using the Chi-squared test (or Fisher\'s exact test for cell frequencies \<5) for categorical variables (α=0.05) and the Kruskal--Wallis test for continuous variables (α=0.05).

Time periods were presented as median (interquartile range (IQR)) and were also categorised into \<2, 2--4 and \>4 months. Differences between age groups were tested using the Chi-squared, Fisher\'s exact and Kruskal--Wallis tests, and were presented using Kaplan--Meier survival curves (with the log-rank test). Cox regression was used to investigate factors associated with each time period. Associations were expressed as hazard ratios (HRs), with HR \>1 indicating a faster rate (shorter time) and HR \<1 indicating a slower rate (longer time). Univariate and age-adjusted models (using age as a continuous exposure variable) were fitted, and factors that had evidence (p\<0.1) of an association with time period (after adjustment for age) were carried forward to a (fully adjusted) multivariable model. All models were probability weighted to take into account sampling from the patient population aged 18--64 years.

Statistical analyses were performed using Stata version 13 (StataCorp, College Station, TX, USA).

Ethics {#s2f}
------

Ethics were reviewed by the Research and Development Dept of London North West Healthcare NHS Trust. Given the retrospective nature of the data, which were collected from routine clinical practice, the recommendation was that research ethics approvals from the Health Research Authority were not required.

Results {#s3}
=======

Patient characteristics {#s3a}
-----------------------

### Age, ethnicity and place of birth {#s3a1}

1023 patients were included in the analyses: 679 patients aged 18--64 years and 344 patients aged ≥65 years ([table 1](#TB1){ref-type="table"}).

###### 

Baseline characteristics in older (age ≥65 years) *versus* younger (18--64 years) patients with tuberculosis (TB)

                                                      **Younger patients (18--64 years)**   **Older patients (≥65 years)**   **p-value**
  -------------------------------------------------- ------------------------------------- -------------------------------- -------------
  **Patients**                                                        679                                344                
  **Age years**                                                   31 (26--42)                        73 (69--78)            
  **Sex**                                                                                                                       0.13
   Female                                                         261 (38.4)                          149 (43.3)            
   Male                                                           418 (61.6)                          195 (56.7)            
  **Ethnicity**                                                                                                                 0.001
   Afghani                                                         11 (1.6)                            9 (2.6)              
   Black                                                           89 (13.1)                          44 (12.8)             
   Indian                                                         437 (64.4)                          193 (56.1)            
   Nepalese                                                        25 (3.7)                            6 (1.7)              
   Pakistani                                                       32 (4.7)                            14 (4.1)             
   Sri Lankan                                                      17 (2.5)                            11 (3.2)             
   White                                                           42 (6.2)                           53 (15.4)             
   Other                                                           26 (3.8)                            14 (4.1)             
  **UK born**                                                      56 (8.2)                           39 (11.4)                 0.10
  **HIV positive**                                              12 (2.8) n=431                      1 (0.9) n=112               0.24
  **Site of TB**                                                                                                            
   Pulmonary                                                      243 (35.8)                          169 (49.1)            
   Extrapulmonary                                                 436 (64.2)                          175 (50.8)                0.001
    Pleural                                                        74 (10.9)                          45 (13.1)                 0.30
    Intrathoracic lymph node                                      117 (17.2)                          46 (13.4)                 0.11
    Extrathoracic lymph node                                      218 (32.1)                          63 (18.3)                 0.001
    Gastrointestinal                                               49 (7.2)                            20 (5.8)                 0.39
    Central nervous system                                         20 (3.0)                            11 (3.2)                 0.82
    Spinal                                                         46 (6.8)                            27 (7.9)                 0.53
    Miliary                                                        13 (1.9)                            15 (4.4)                 0.02
  **Culture results**                                                                                                       
   *M. tuberculosis* culture positive  (all cases)                388 (65.4)                          177 (61.0)                0.20
   *M. tuberculosis* culture positive  (PTB)                      162 (73.0)                          100 (69.0)                0.41
   Smear positive (PTB)                                            67 (29.1)                          33 (25.0)                 0.40
  **Biochemistry**                                                                                                          
   ESR mm·h^−1^                                                33 (13--67) n=273                  28 (18--72) n=205             0.04
   Albumin g·L^−1^                                             37 (31--39) n=318                  33 (28--39) n=287            \<0.001
   ALT IU·L^−1^                                                21 (14--36) n=317                  19 (12--29) n=287             0.007
   ALT \>50 IU·L^−1^                                            41 (12.9) n=317                     34 (9.9) n=345          
   ALP IU·L^−1^                                               91 (77--112) n=318                  96 (79--128) n=287            0.005
   Bilirubin µM·L^−1^                                           8 (6--11) n=312                    8 (6--12) n=285              0.77
   Sodium mmol·L^−1^                                         138 (136--140) n=317                137 (133--140) n=286           0.001
   Creatinine µM·L^−1^                                         63 (57--69) n=317                  86 (68--105) n=286           \<0.001
   Creatinine \>112 µM·L^−1^                                     3 (0.9) n=318                     71 (22.2) n=320             \<0.05
   Vitamin D nmol·L^−1^                                         1 (1--8) n=275                     6 (1--31) n=205              0.001
   Vitamin D \>50 nmol·L^−1^                                     1 (0.4) n=275                     36 (17.6) n=205              0.001

Data are presented as n, median (interquartile range) or n (%), unless otherwise stated. *M. tuberculosis*: *Mycobacterium tuberculosis*; PTB: pulmonary TB; ESR: erythrocyte sedimentation rate; ALT: alanine aminotransferase; ALP: alkaline phosphatase.

61.6% of the younger group and 56.7% in the older group were male (p=0.13). Ethnicity was distributed differently across the two age groups (p=0.001): South Asian ethnicity (Indian, Afghani, Nepalese, Pakistani and Sri Lankan) accounted for 76.9% of cases in younger patients and 67.8% of cases in older patients, while the proportion of White patients was 6.2% in the younger cohort and 15.4% in the older cohort.

### Biochemistry and vitamin D levels {#s3a2}

There was evidence of differences in all biochemistry measures except bilirubin. Vitamin D levels differed significantly between the two groups, but both were low at a median of 1 and 6 nmol·L^−1^ for younger and older patients, respectively. Only 0.4% of patients aged \<65 years *versus* 17.6% of patients aged ≥65 years had a vitamin D level \>50 nmol·L^−1^.

Site of TB {#s3b}
----------

35.8% of younger patients and 49.1% of older patients had PTB (p=0.001) ([table 1](#TB1){ref-type="table"} and [figure 1](#F1){ref-type="fig"}). Extrathoracic TB lymphadenitis was less common (18.3% *versus* 32.1%; p=0.001) and miliary TB more common (4.4% *versus* 1.9%; p=0.02) in older compared with younger EPTB patients.

![Site of tuberculosis (TB) in the younger group (aged 18--64 years) and the older group (aged ≥65 years): pulmonary TB (PTB) *versus* extrapulmonary TB (EPTB), with specific sites for EPTB also shown. ITLN: intrathoracic lymph node; ETLN: extrathoracic lymph node; GI: gastrointestinal; CNS: central nervous system. \*: p\<0.05.](00228-2018.01){#F1}

Clinical symptoms {#s3c}
-----------------

The "classical" symptoms of TB, including cough, haemoptysis, fever, drenching night sweats and weight loss, were more common among PTB patients in the younger cohort (p\<0.05) ([table 2](#TB2){ref-type="table"}). When EPTB patients were included the differences remained for cough, fever, drenching night sweats and dyspnoea, but not for haemoptysis and weight loss. The less specific symptoms of dyspnoea, lethargy and reduced appetite were more common among older patients when all sites of TB were included, but only dyspnoea was statistically significant.

###### 

Symptoms at presentation of the younger group (aged 18--64 years) and the older group (aged ≥65 years) with tuberculosis (TB) and pulmonary TB (PTB)

                                **All TB patients**   **PTB patients**                                   
  ---------------------------- --------------------- ------------------ ------- ------------ ----------- -------
  **Patients**                          629                 136                     218          72      
  **Cough**                         236 (37.5)           38 (27.9)       0.035   140 (64.2)   31 (43.1)   0.002
  **Haemoptysis**                    32 (5.1)             2 (1.5)        0.063   27 (12.4)     2 (2.8)    0.03
  **Fever**                         194 (30.8)           18 (13.2)       0.001   84 (38.5)    11 (15.2)   0.001
  **Drenching night sweats**        159 (25.3)            12 (8.8)       0.001    72 (33)      7 (9.7)    0.001
  **Weight loss**                   226 (36.0)           42 (30.9)       0.26    113 (51.8)   27 (37.5)   0.04
  **Dyspnoea**                       37 (5.9)            28 (20.6)       0.001   22 (10.1)    21 (29.2)   0.001
  **Lethargy**                       30 (4.8)             10 (7.4)       0.22     9 (4.1)      6 (8.3)    0.16
  **Reduced appetite**               37 (5.9)            16 (11.8)       0.70     18 (8.3)     7 (9.7)    0.70

Data are presented as n or n (%), unless otherwise stated.

Radiology {#s3d}
---------

There were some differences in the chest radiography appearance of PTB patients: cavitation was more common among younger than older patients (18.3% *versus* 10.3%; p=0.001), as was lymphadenopathy (19.5% *versus* 4.1%; p=0.001). Apparent differences in nodules (16.1% *versus* 10.3%) and effusions (13.7% *versus* 7.2%) were not supported by statistical evidence ([table 3](#TB3){ref-type="table"}). Miliary TB was seen more frequently in older patients (4.1% *versus* 2.9%) and mirrored the rates of clinically classified miliary TB. Around half of the patients in both groups had consolidation on their chest radiographs.

###### 

Radiological differences between younger (aged 18--64 years) and older (aged ≥65 years) patients with pulmonary tuberculosis (PTB)

                                                          **Younger patients (18--64 years)**   **Older patients (≥65 years)**   **p-value**
  ------------------------------------------------------ ------------------------------------- -------------------------------- -------------
  **Patients**                                                            679                                344                
  **Patients with PTB**                                               243 (35.7)                          169 (49.1)                0.001
  **Patients with PTB with chest radiography reports**                241 (99.2)                          97 (57.4)             
  **Chest radiography changes**                                                                                                 
   Cavitation                                                          44 (18.3)                          10 (10.3)                 0.001
   Consolidation                                                      116 (48.1)                          49 (50.5)                 0.692
   Nodules                                                             39 (16.1)                          10 (10.3)                 0.165
   Miliary                                                              7 (2.9)                            4 (4.1)                  0.568
   Lymphadenopathy                                                     47 (19.5)                           4 (4.1)                  0.001
   Effusion                                                            33 (13.7)                           7 (7.2)                  0.095

Data are presented as n or n (%), unless otherwise stated.

Timing of events {#s3e}
----------------

### Time to presentation (from symptom onset) {#s3e1}

Considering all cases of TB, the median duration of symptoms at presentation to secondary care was longer in older patients (60 days) compared with younger patients (45 days), but this difference was not supported by statistical evidence (p=0.3). 27.5% of older patients were symptomatic for \>4 months compared with 21.0% of younger patients (p=0.53).

For PTB, the median duration of symptoms was 60 days in younger patients compared with 75 days in older patients, but this was not statistically significant (p=0.40). For pleural, intrathoracic and extrathoracic lymph node TB, the median duration in younger patients was 30, 30 and 50 days, respectively, and for older patients it was 26, 30 and 60 days, respectively (supplementary table S1).

### Time from presentation (to starting treatment) {#s3e2}

For all TB cases, the median time from presenting in secondary care to starting treatment was shorter in younger compared with older patients: 3 *versus* 15 days (p=0.001). For those with PTB, the median duration was 2 *versus* 7 days in younger *versus* older patients (p=0.001). The time to starting treatment for EPTB was also longer in older patients. For pleural, intrathoracic and extrathoracic lymph node TB, the median time in younger patients was 3, 18 and 5 days, respectively, and for older patients it was 29, 42 and 11 days, respectively.

### Time to treatment (from symptom onset) {#s3e3}

Total time from symptom onset to starting treatment was 50% longer for older patients (91 days) than for younger patients (61 days) (p=0.001) for all patients with TB. The findings for those with PTB alone were similar at 61 *versus* 92.5 days in younger *versus* older patients with PTB ([table 4](#TB4){ref-type="table"}). The total time from symptom onset to starting treatment was longer for older patients with EPTB. For pleural, intrathoracic and extrathoracic lymph node TB, the median time in younger patients was 35, 63 and 61 days, respectively, and for older patients it was 54, 84 and 94 days, respectively.

###### 

Symptom duration at presentation to secondary care, time to starting treatment from presentation to secondary care and total time to starting treatment from symptom onset among older (aged ≥65 years) and younger (18--64 years) patients with tuberculosis (TB) and pulmonary TB (PTB)

                                                                                **Younger patients (18--64 years)**   **Older patients (≥65 years)**   **p-value all patients**   **p-value PTB patients**          
  ---------------------------------------------------------------------------- ------------------------------------- -------------------------------- -------------------------- -------------------------- ------- -------
  **Patients**                                                                                  523                                182                           109                         53                     
  **Symptom duration at presentation to secondary care days**                              45 (22.5--90)                       60 (30--90)                   60 (15--135)               75 (11--180)         0.30    0.40
  **Symptom duration**                                                                                                                                                                                              
   \<2 months                                                                               257 (39.1)                                                        51 (46.8)                                      0.66   
   2--4 months                                                                              156 (39.9)                                                        28 (25.7)                                      0.39   
   \>4 months                                                                               110 (21.0)                                                        30 (27.5)                                      0.16   
  **Time to starting treatment from presentation to secondary care to days**                 3 (1--18)                           2 (1--6)                     15 (3--59)                 7 (2--53)           0.001   0.001
  **Total time to starting treatment from symptom onset days**                              61 (31--96)                        61 (31--103)                  91 (46--182)             92.5 (41.5--189)       0.001   0.003
  **Time to treatment**                                                                        n=506                              n=164                         n=102                       n=49                    
   \<2 months                                                                               269 (53.2)                          75 (45.7)                     34 (33.3)                  17 (34.7)           0.001   0.001
   \<4 months                                                                               405 (80.0)                          128 (78.0)                    66 (64.7)                  31 (63.3)                  
   \>4 months                                                                               101 (20.0)                          36 (22.0)                     36 (35.3)                  18 (36.7)                  

Data are presented as n, median (interquartile range) or n (%), unless otherwise stated.

### Across age groups {#s3e4}

Symptom duration at presentation to secondary care, time to starting treatment from presentation to secondary care and total time to start treatment from symptom onset to starting treatment are shown across age groups in [figure 2](#F2){ref-type="fig"}. The median (IQR) time from secondary care to treatment for patients aged 65--74, 75--84 and 85--94 years was 18.5 (4--60), 13 (3--54) and 9 (2--36) days, respectively, compared with 6 (1--32) days for patients aged 55--64 years.

![Symptom duration at presentation to secondary care, time to starting treatment from presentation to secondary care and total time to starting treatment from symptom onset. \*\*: p\<0.01.](00228-2018.02){#F2}

### Factors associated with time to treatment {#s3e5}

Age (as a continuous variable) was associated with longer time to presentation at secondary care (HR 0.98 (95% CI 0.98--0.99) per year of age) ([table 5](#TB5){ref-type="table"}), longer time to starting treatment (HR 0.98 (95% CI 0.98--0.99) per year of age) ([table 6](#TB6){ref-type="table"}) and longer time from symptom onset to starting treatment (HR 0.98 (95% CI 0.98--0.99) per year of age) ([table 7](#TB7){ref-type="table"}). These associations were unchanged in multivariable models when adjusted for other factors. TABLE 5Factors associated with time to presentation (symptom duration) at secondary care**Crude HR (95% CI)Age-adjusted HR (95% CI)Fully adjusted HR (95% CI)^\#^Age**0.98 (0.98--0.99)0.98 (0.98--0.99)**Sex (male *versus* female)**1.19 (1.03--1.38)1.20 (1.03--1.34)0.85 (0.71--1.02)**Ethnic group** Indian1.08 (0.85--1.37) Pakistani1.10 (0.79--1.53) Afghani0.58 (0.46--0.73) White0.78 (0.55--1.10) Bangladeshi1.03 (0.62--1.72) Black0.91 (0.67--1.22) Chinese4.27 (3.22--5.67)**HIV**1.50 (0.93--2.42)2.08 (1.31--3.30)0.71 (0.46--1.09)**Diabetes**1.26 (1.01--1.58)1.09 (0.85--1.40)**Hypertension**1.19 (0.96--1.46)1.01 (0.80--1.30)**Renal failure**1.11 (0.90--1.37)**Cancer**1.33 (0.82--2.16)**Lung disease** Asthma/COPD1.59 (0.58--4.33) Bronchiectasis1.28 (0.54--3.00) ILD1.09 (0.33--3.65) PE4.04 (1.48--11.00)**PTB *versus* EPTB**1.20 (1.03--1.38)1.17 (1.00--1.37)1.26 (1.05--1.50)HR: hazard ratio; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; PE: pulmonary embolism; PTB: pulmonary tuberculosis; EPTB: extrapulmonary tuberculosis. ^\#^: adjusted for age, sex, HIV and PTB *versus* EPTB. TABLE 6Factors associated with time to starting treatment (from presentation to secondary care)**Crude HR (95% CI)Age-adjusted HR (95% CI)Fully adjusted HR (95% CI)**^\#^**Age**0.98 (0.98--0.99)0.98 (0.98--0.99)**Sex (male *versus* female)**1.17 (1.01--1.35)1.19 (1.01--1.38)1.09 (0.94--1.29)**Ethnic group** Indian1.03 (0.84--1.26) Pakistani0.75 (0.49--1.17) Afghani0.24 (0.19--0.29) White0.90 (0.63--1.28) Bangladeshi1.16 (0.61--2.21) Black0.94 (0.71--1.24) Chinese0.89 (0.49--1.64)**UK born**0.96 (0.71--1.31)1.00 (0.72--1.40)**Sputum smear**1.09 (1.01--1.18)1.10 (1.01--1.20)1.09 (0.90--1.32)**TB sensitivity**1.27 (1.11--1.44)0.84 (0.70--1.01)**HIV**1.03 (0.74--1.43)**Diabetes**1.36 (1.13--1.64)1.14 (0.92--1.40)**Hypertension**1.55 (1.29--1.87)1.33 (1.06--1.67)0.86 (0.65--1.12)**Renal failure**1.28 (1.13--1.46)1.16 (0.99--1.35)**Cancer**1.54 (1.20--1.97)1.23 (0.90--1.69)**Lung disease** Asthma/COPD0.83 (0.29--2.37) Bronchiectasis3.16 (0.99--10.1) ILD1.27 (0.39--4.19) PE1.22 (3.91--3.78) Sarcoid1.10 (0.42--2.90)**PTB *versus* EPTB**0.74 (0.64--0.86)0.70 (0.60--0.82)1.10 (0.90--1.34)**Cough**1.22 (1.06--1.40)1.22 (1.06--1.41)0.97 (0.81--1.15)**Sweats**1.38 (1.18--1.61)1.33 (1.12--1.56)1.24 (1.02--1.51)**Weight loss**1.24 (1.08--1.43)1.25 (1.08--1.44)1.03 (0.87--1.22)HR: hazard ratio; TB: tuberculosis; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; PE: pulmonary embolism; PTB: pulmonary tuberculosis; EPTB: extrapulmonary tuberculosis. ^\#^: adjusted for age, sex, sputum smear, hypertension, PTB *versus* EPTB, cough, sweats and weight loss TABLE 7Factors associated with time to starting treatment from symptom onset**Crude HR (95% CI)Age-adjusted HR (95% CI)Fully adjusted HR (95% CI)**^\#^**Age**0.98 (0.98--0.99)0.98 (0.98--0.99)**Sex (male *versus* female)**1.22 (1.04--1.43)1.23 (1.05--1.46)0.85 (0.72--1.00)**Ethnic group**0.98 (0.94--1.02)0.98 (0.95--1.02)**UK born**0.92 (0.67--1.27)1.23 (1.05--1.46)1.05 (0.77--1.43)**Sputum smear**0.98 (0.90--1.07)0.97 (0.88--1.06)**TB sensitivity**1.14 (0.99--1.32)0.98 (0.82--1.18)**HIV**1.37 (0.93--2.02)2.07 (1.30--3.29)0.71 (0.46--1.07)**Diabetes**1.55 (1.21--1.99)1.26 (0.97--1.64)**Hypertension**1.40 (1.13--1.73)1.14 (0.90--1.44)**Renal failure**1.22 (0.99--1.51)1.11 (0.86--1.45)**Cancer**1.27 (0.82--1.98)**Lung disease** Asthma/COPD1.78 (0.67--4.69) Bronchiectasis2.26 (0.74--6.90) ILD1.41 (0.32--6.16) PE5.64 (1.87--17.01) Sarcoid28.2 (5.91--124.76)**PTB *versus* EPTB**1.01 (0.93--1.30)**Cough**1.07 (0.91--1.25)**Sweats**1.22 (1.03--1.44)1.15 (0.97--1.37)**Weight loss**0.90 (0.77--1.05)HR: hazard ratio; TB: tuberculosis; COPD: chronic obstructive pulmonary disease; ILD: interstitial lung disease; PE: pulmonary embolism; PTB: pulmonary tuberculosis; EPTB: extrapulmonary tuberculosis. ^\#^: adjusted for age, sex, UK born and HIV.

When adjusted for age, the factors associated with a shorter time to presentation at secondary care were sex (male *versus* female) (HR 1.20 (95% CI 1.03--1.34)), HIV (HR 2.08 (95% CI 1.31--3.30)) and PTB *versus* EPTB (HR 1.17 (95% CI 1.00--1.37)). Of these factors, only age and PTB *versus* EPTB remained as independent predictors in a multivariable model (HR 1.26 (95% CI 1.05--1.50)) ([table 5](#TB5){ref-type="table"}).

When adjusted for age, factors associated with a shorter time from presentation to secondary care included sex (male *versus* female), positive sputum smear, hypertension, cough, sweats and weight loss. A shorter time from presentation to starting treatment was associated with PTB *versus* EPTB. In a multivariable model, only age and sweats remained as independent predictors ([table 6](#TB6){ref-type="table"}).

When adjusted for age, factors associated with a shorter time to treatment (from symptom onset) included sex (male *versus* female) (HR 1.23 (95% CI 1.05--1.46)), UK born (HR 1.23 (95% CI 1.05--1.46)) and HIV (HR 2.07 (95% CI 1.30--3.29)). Only age remained as an independent predictor in a multivariable model adjusted for each of these variables ([table 7](#TB7){ref-type="table"}).

Discussion {#s4}
==========

In this cohort, older age was associated with a longer time from symptom onset to starting treatment for TB. Symptom duration at presentation to secondary care did not differ between the two groups and the overall difference was attributed to longer time to starting treatment after presentation to secondary care. A greater proportion of older patients were symptomatic for \>4 months compared with younger patients. The clinical and radiological presentations of older patients were different to younger patients with TB: older patients had fewer of the "classical" symptoms of TB and more non-TB specific symptoms, including dyspnoea and lethargy. Cavitation, nodules, lymphadenopathy and effusions were more common on chest radiography in younger than in older patients.

The higher proportion of South Asian patients noted in the younger age group with active TB is likely to represent trends in immigration to the UK, where we typically observe the phenomenon of young Asian males living in low-rental areas of London where there is a community of their compatriots and having full-time or part-time low-paid jobs in food or other factories or in construction. This and the peak of TB in this age group may give a biased perception of the "typical" patient with TB in the UK, perhaps contributing to a lower index of clinical suspicion of TB in older or White patients. Public Health England reported that 25% of patients with PTB commenced treatment at least 4 months after symptom onset, but this proportion increased to 33% of UK-born cases and 35% of those aged ≥65 years \[[@C22]\].

The difference in clinical presentation has been borne out in other studies in Turkey \[[@C6], [@C23]\], although some report a similar prevalence of respiratory symptoms \[[@C24]\]. The differences in clinical and radiological presentations are likely as a result of the effect of immunosenescence on the characteristics of TB in older compared with younger patients with TB; similar distortions occur in other immunocompromised states, *e.g.* HIV \[[@C25]\]. It has long been hypothesised that TB in the elderly results from reactivation of LTBI rather than recently acquired infection. TB prevalence in England before the advent of chemotherapy in the 1950s was high and UK-born older patients may have developed LTBI in childhood or early adulthood \[[@C26]\]. Changes relating to immunosenescence, or the onset of comorbidities which influence the immune system, may contribute to reactivation \[[@C1], [@C12], [@C13], [@C27]\]. Generally, LTBI reactivation is most likely to occur within 18 months of exposure \[[@C28]\]. This is unlikely to be the case in our older patients, because rates of transmission of TB in London are low \[[@C22]\]. The exception may be where the elderly live in a closed environment, with nursing home residents having an increased risk of TB \[[@C29]\]. Some older studies that describe drug resistance across age groups show that monoresistance (to isoniazid or streptomycin) in older patients is only slightly lower than in younger patients, suggesting that recent transmission may be important \[[@C30], [@C31]\].

In our study, we find that EPTB is significantly more common among younger patients than PTB (64% *versus* 35%) compared with ∼50% of each among older patients. There is some tentative evidence in the literature that PTB is more common than EPTB among older patients, which would be consistent with TB in the elderly being predominantly as a result of reactivation. T[eale]{.smallcaps} *et al.* \[[@C32]\] reported that PTB accounted for 87% of cases in the elderly compared with 75% of cases in younger patients in the UK. Another study (in India) found PTB to be similar at 75% in older patients and 73% in younger patients; the most common site of EPTB in older patients was TB lymphadenitis \[[@C9]\]. The different ratios of EPTB and PTB in older and younger patients in our cohort is possibly related to the pattern of reactivation and differences of presentation of TB resulting from immunosenescence related to ageing \[[@C33]\]. There are few phylogenetic studies that characterise this in older populations. A Japanese variable number tandem repeat study analysed 387 strains of *Mycobacterium tuberculosis* among elderly patients and found that 9.7% of the cases were attributable to recent transmission; this supports the suggestion that TB in this population is as a result of endogenous reactivation from infection at a time when TB was more prevalent \[[@C34]\]. Another explanation for the difference may also relate to differences in dominant ethnicities, with South Asian ethnicity more common in the younger age group compared with White ethnicity in the older age group; both age and ethnicity have been shown to influence the site of TB, with EPTB being more common among ethnicities from outside of Europe \[[@C35]\].

There are few studies that compare treatment delays in the UK between younger and older patients. L[ewis]{.smallcaps} *et al*. \[[@C36]\] found an overall delay of 126 days, which is longer than in our cohort; the median duration of symptoms was similar at 63 days, but the healthcare delay was longer at 35 days. The contribution of primary *versus* secondary care delays was not clarified, making direct comparison with our study difficult. Another UK study found that female sex and older age were contributors to delays in starting treatment \[[@C37]\]. Of note, we did not find ethnicity to be a cause of delay; however, the numbers of White patients in this study are small (42 in those aged 18--65 years and 53 in those aged ≥65 years), which may account for this. Time to starting treatment from presentation to secondary care was shorter for EPTB compared with PTB in this cohort, which differs from published studies \[[@C38]\]. This is likely due to the rapidity with which diagnostics are carried out and treatment initiated in EPTB patients at this site, *e.g.* lymph node or pleural aspirate compared with awaiting sputum samples or bronchoalveolar lavage for patients with PTB.

A UK study using data routinely collected between 1999 and 2000 showed that White ethnicity, female sex and older age contributed to delays in the West Midlands \[[@C39]\]. A North London study in 2004 reported delays between 78 and 99 days, comprising patient-related delays of 35--54 days and healthcare system delays of 30 days. Shorter delays occurred in patients from high-prevalence countries, younger patients and those with smear-positive disease \[[@C40]\]. The difference in time to starting treatment may relate to the more classical symptoms of TB evident in younger patients or the absence of comorbidities that alter the course of TB. Concerns about drug interactions, polypharmacy or drug side-effects in older patients may influence the decision to start TB treatment.

TB mortality increases with age \[[@C41]\]. In 2015, there were 1.8 million TB-related deaths worldwide \[[@C42]\]; in 2014, in the UK, of the 6405 with sensitive TB, 5.5% had death as an outcome \[[@C22]\], with those aged ≥65 years accounting for 66.4% of deaths \[[@C22]\]. According to the 2010 Global Burden of Disease estimates, \>50% of TB deaths occur in those aged ≥65 years internationally \[[@C4]\]. In the UK, those aged ≥65 years accounted for 66.4% of 351 deaths \[[@C22]\]. In a Chinese study, those aged ≥65 years had twice the risk of death as those aged 18--64 years \[[@C43]\]. In the UK, deaths are broken down to further categories, as older patients may also die of other causes where TB is not the main cause, may be a contributor or may not be contributing \[[@C22]\]. However, the higher proportion of deaths accounted for by older patients with TB supports the need to invest in measures to ensure the appropriate investigation and management of older patients with TB.

A constraint of this study is that presentation at secondary care rather than primary care is taken as the time-point for presenting to healthcare, because this was readily available from the databases. There may have been more incorrectly recorded data for older patients (because we used data from 2002 to 2015), but this is unlikely to bias our measures of effect. Bias could have occurred in relation to recall of time of symptom onset, if older patients tended to recall longer or shorter time since onset. This can be hard to address, although obtaining primary healthcare records from where patients were initially seen could corroborate reported symptoms and durations. In addition, missing data occurred in a greater proportion of older patients compared with younger patients. This is due to the different time periods, with more radiography reports available in later time periods. However, given the magnitude of the differences noted, this is unlikely to alter the results that are statistically significant.

In summary, our analysis of data from a large UK cohort of TB patients has demonstrated different clinical and radiological presentations between older and younger TB patients, and longer time to TB treatment for older patients, which was a cumulative effect of longer time to presentation and longer time from presentation to initiation of treatment. These differences may relate to the lower index of suspicion of TB in the elderly, but also to the effect of immunosenescence on the classical presentations of TB. These findings relate to an urban cohort that had a high burden of TB during the study period in a country that has a low incidence of TB and they will be applicable in similar settings in Western Europe.
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TABLE S1 This table shows the symptom duration at presentation to secondary care, time to starting treatment from presenting to secondary care and total time from symptom onset to starting treatment among older (aged ≥65 years) and younger patients (18-64 years) with pleura, intrathoracic and extrathoracic lymph node TB00228-2018.tableS1
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